# Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer

> **NCT00801242** · PHASE3 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 220 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Degarelix 240 mg / 80 mg

## Key facts

- **NCT ID:** NCT00801242
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2012-06
- **Final completion:** 2013-07
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2014-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00801242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00801242, "Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00801242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*